Avenzo Therapeutics Announces Global License Of AVZO-021 (ARTS-021), A Clinical Stage CDK2 Inhibitor From Allorion Therapeutics January 10, 2024
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted ADC January 10, 2024
Orion and Glykos announce research collaboration and licensing agreement to develop next-generation ADCs January 10, 2024
Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program December 19, 2023
Glycotope and Evotec enter licensing agreement to combine Glycotope antibodies and Evotec’s immune cell engager platform December 19, 2023
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degrader-Antibody Conjugates (DACs) December 19, 2023
FDA guides on the next Ph 2 study for advancement of Next Generation Capecitabine (“NGC-Cap”) for cancer patients December 19, 2023
Boehringer Ingelheim expands immuno-oncology portfolio with the acquisition of bacterial cancer therapy specialist T3 Pharma December 11, 2023
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio December 11, 2023
Jazz Pharmaceuticals and MD Anderson Announce Five-Year Collaboration to Evaluate Zanidatamab in HER2-Expressing Cancers December 11, 2023
BeiGene and Ensem Therapeutics Announce Partnership to Advance Differentiated CDK2 Inhibitor December 11, 2023
First Patient Dosed in Ph 1a Trial of QN-302 in Advanced or Metastatic Solid Tumors December 11, 2023
Interim Data from Ph 1b/2 Clinical Trial of Nana-val in Patients with EBV+ve Solid Tumors Show Confirmed Tumor Responses at Higher Dose Levels December 11, 2023
Successful Completion and Interim Results of Ph 1 Study of HC-5404 in Solid Tumors announced December 11, 2023
First Patient Dosed in Ph 1 Trial of ORB-011 in Patients with Advanced Solid Tumors November 20, 2023
Prelude Therapeutics and AbCellera Enter Partnership to Develop First-in-Class Precision ADCs in Oncology November 7, 2023
Merck Strengthens Oncology Pipeline Through Strategic Partnership with Hengrui for Next-Gen Selective PARP1 Inhibitor and ADC November 7, 2023
AstraZeneca announces collaboration and investment agreement with Cellectis to accelerate cell therapy and genomic medicine ambitions November 7, 2023
Caris Life Sciences and Moderna Announce Multi-Year Strategic Partnership to Advance mRNA-Based Oncology Therapeutics October 31, 2023
